Although SOC have been reported to be an important clinical strategy to treat IPF patients, over the years, the advance of senotherapeutics in preclinical model aligned with outstanding preliminary results of clinical trials, have proved the importance of targeting senescent cells in IPF, and clearly, SOC did not have a significant impact on senescent lung fibroblasts . The gene discussed is UBXN11; the disease is idiopathic pulmonary fibrosis.